Abstracts tagged "Myositis"

Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 1291 • 2019 ACR/ARP Annual Meeting
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Katerina Kubinova¹ and Jiří Vencovský ², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Prometheus study was a prospective, randomized, assessor-blind multicenter trial, comparing the efficacy and safety of the glucocorticoid (GC) monotherapy versus combination therapy with methotrexate…
Abstract Number: 1292 • 2019 ACR/ARP Annual Meeting
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ilana Golub ², Ani Shahbazian ³, Jennifer Wang ³ and Christina Charles-Schoeman ⁴, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Los Angeles, ⁴University of California, Los Angeles, CA
Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL)…
Abstract Number: 480 • 2018 ACR/ARHP Annual Meeting
Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data
Laura Tasan¹, Emily Brunner², Judy Squires³, Rohit Aggarwal⁴, Chester V. Oddis⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch⁶, Emily Mirizio⁷ and Kathryn S. Torok², ¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁶Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁷Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: There is an unmet need for more objective disease outcome measures in Juvenile Myositis (JM) patients. This pilot study sought to test the reliability,…
Abstract Number: 1210 • 2018 ACR/ARHP Annual Meeting
Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
Kristofoor Leeuwenberg¹, Lisa Christopher-Stine¹, Clifton O. Bingham III², Julie J. Paik², Eleni Tiniakou³, Seth Billings⁴, Philippe Burlina⁴ and Jemima Albayda⁵, ¹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University Applied Physics Lab, Laurel, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The use of ultrasound in the assessment of muscle conditions has grown over the years. Various myopathies have shown an increase in echo intensity…
Abstract Number: 1334 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies
Jiram Torres-Ruíz¹, Araceli Leal-Alanis², Ricardo Vazquez-Rodriguez³, Mario René Alvarado-Lara³, Edgar Rafael Carazo-Vargas³, José Luis Maravillas-Montero⁴, Jorge Alcocer-Varela⁵ and Diana Gómez-Martín⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁴Red de Apoyo a la Investigación, UNAM, Mexico, Mexico, ⁵Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Low density granulocytes (LDGs) are a subset of neutrophils that spontaneously produce neutrophil extracellular traps (NETs) and type I IFN. The latter correlates with…
Abstract Number: 1338 • 2018 ACR/ARHP Annual Meeting
Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
Angelika Lackner¹, Viktoria Tiefenthaler², Jalia Mirzayeva², Winfried Graninger³ and Martin Stradner⁴, ¹Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Department of Rheumatology & Immunology, Medical University of Graz, Graz, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Validation of the diagnostic accuracy of myositis-related antibodies in a large patient-cohortLackner, A; Tiefenthaler, V; Mirzayeva, J; Graninger, W; Stradner, MH Background/Purpose: Myositis-specific antibodies (MSA) and…
Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi^1,2, William Warren-Hicks³, Nastaran Bayat¹, Ira Targoff⁴, Terri H Finkel⁵, Ellen Goldmuntz⁶, Michael Henrickson⁷, Bianca Lang⁸, Andrew Mammen⁹, Lauren M. Pachman¹⁰, Murray Passo¹¹, Terrance P. O'Hanlon¹, Frederick W. Miller¹, Michael Ward⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³EcoStat, Inc., Mebane, NC, ⁴VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, ⁶NIAID, NIH, Bethesda, MD, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC
Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
Abstract Number: 2286 • 2018 ACR/ARHP Annual Meeting
Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
Jean Patrick Laporte¹, Florent Garrigues², Anais Huwart², Sandrine Jousse-Joulin³, Thierry Marhadour¹, Dewi Guellec³, Divi Cornec⁴, Valérie Devauchelle-Pensec³ and Alain Saraux³, ¹CHU Brest, Brest, France, ²Radiology, CHU Brest, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France
Background/Purpose: To assess the prevalence of myofascial inflammatory lesions visible by magnetic resonance imaging (MRI) and their changes after tocilizumab therapy in active polymyalgia rheumatica…
Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Emanuele Calabresi¹, Simone Barsotti², Elisa Cioffi³, Alessandra Tripoli¹, Andrea Delle Sedie¹, Laura Bazzichi⁴, Ornella Mazzarella¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Takahisa Gono¹, Kenichi Masui², Naoshi Nishina³, Shinji Sato⁴ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, Show University Hospital, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…
Abstract Number: 379 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
Julien Campagne¹, Thomas Moulinet², Jonathan Epstein³, Sabine Revuz⁴, Francois Maurier⁵, Marie-Hélène Schuhmacher⁶, Philippe Evon⁷, Alain Meyer⁸ and Roland Jaussaud², ¹Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, ²Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, ³Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ⁴Médecine Interne, Hôpitaux Privés de Metz, Metz, France, ⁵Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁶Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, ⁷Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, ⁸Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS),…
Abstract Number: 381 • 2018 ACR/ARHP Annual Meeting
Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
David Amici^1,2, Iago Pinal-Fernandez^3,4, Ruben Pagkatipunan⁵, Albert Mears⁵, Rebecca De Lorenzo⁶, Eleni Tiniakou⁷, Jemima Albayda³, Julie J. Paik⁷, Thomas E. Lloyd⁸, Lisa Christopher-Stine⁹, Andrew Mammen^8,10 and Tae Chung¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ¹⁰National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹¹Johns Hopkins University, Baltimore, MD
Background/Purpose: To assess muscle function in myositis patients, clinicians typically use manual muscle testing (MMT), a measure of maximal isometric strength. However, patients with high…
Abstract Number: 384 • 2018 ACR/ARHP Annual Meeting
Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
Bret Sohn¹, Narender Annapureddy², Rosemarie Dudenhofer³, April Barnado¹, Leslie Crofford¹ and Erin Wilfong⁴, ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Division of Rheumatology and Immunology, Vanderbilt Unversity Medical Center, Nashville, TN
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in connective tissue diseases (CTDs). The purpose of this study is to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.